top of page
ABOUT OVO
Manufacturing viral vaccines is complex. One of the biggest challenges is the formation of defective interfering particles (DIPs), unwanted viral particles that can compete with the production of the vaccine itself, reducing yields and limiting manufacturing efficiency.
OVO Biomanufacturing is changing that.
Our technology platform is designed to reduce the impact of defective interfering particles, helping vaccine manufacturers achieve
improvements in viral yield without the need to fundamentally change the manufacturing process.
Could OVO work for your company?
My name is Alexa Young
Briefly introduce yourself and share something interesting with website visitors. Double click to edit the text.
bottom of page